Neurochemical perspectives to the function of monoamine oxidase

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Acta Neurologica Scandinavica, Supplementum

• Publication date

  1989-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1600-0404.1989.tb01781.xPMID 2618592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain

  2005cited by this paper
• L-deprenyl plus l-phenylalanine in the treatment of depression

  2005cited by this paper
• Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson’s disease?

  1989cited by this paper
• Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

  1989cited by this paper
• Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex.

  1989cited by this paper
• Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem.

  1988cited by this paper
• Biochemical fundamentals of Parkinson's disease.

  1988cited by this paper
• Platelet MAO‐B activity and the psychopathology of Parkinson's disease, senile dementia and multi‐infarct dementia

  1988cited by this paper
• Distribution pattern of monoamine oxidase a and monoamine oxidase b in human substantia nigra shown by immunofluorescence cytochemistry on thin frozen sections

  1988cited by this paper
• Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem.

  1988cited by this paper
• Experience with selegiline in the treatment of Parkinson's disease.

  1987cited by this paper
• Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type-A: a pilot study.

  1986cited by this paper
• Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl

  1986cited by this paper
• Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment.

  1986cited by this paper
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

  1985cited by this paper
• Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse.

  1985cited by this paper
• L-Deprenil, A Selective Monoamine Oxidase Type B Inhibitor, in the Treatment of Depression: A Double Blind Evaluation

  1983cited by this paper
• Parkinson's disease: A disorder due to nigral glutathione deficiency?

  1982cited by this paper
• Synaptic density in human frontal cortex - developmental changes and effects of aging.

  1979cited by this paper

• Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

  2025cites this paper
• Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration

  2024cites this paper
• Dopamine-iron homeostasis interaction rescues mitochondrial fitness in Parkinson’s disease

  2023cites this paper
• Multitarget 2'-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities.

  2021cites this paper
• Type A and B monoamine oxidases distinctly modulate signal transduction pathway and gene expression to regulate brain function and survival of neurons

  2018cites this paper
• Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases

  2018cites this paper
• Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders

  2017cites this paper
• Ligands for the dopamine D 2-like receptors

  2017cites this paper
• 3D Mapping Reveals Network-specific Amyloid Progression and Subcortical Susceptibility

  2017cites this paper
• Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review

  2017cites this paper
• Trehalose rescues glial cell dysfunction in striatal cultures from HD R6/1 mice at early postnatal development.

  2016cites this paper
• Association between monoamine oxidase B A644G polymorphism and Parkinson's disease risk: a meta-analysis in the Chinese population.

  2016cites this paper
• Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression

  2016cites this paper
• Premorbid Personality and the Risk of Parkinson’s Disease

  2014cites this paper
• Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

  2013cites this paper
• Monoamine oxidase inhibitors

  2013cites this paper
• Parkinson's disease : workplace risk factors

  2011cites this paper
• Indicators of Early Adult and Current Personality in Parkinson's Disease

  2011cites this paper
• The monoamine oxidase inhibition properties of caffeine analogues containing saturated C–8 substituents

  2010cites this paper
• Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology.

  2009cites this paper
• Iron and Monoamine Oxidase in Brain Function and Dysfunction: Development of Neuroprotective-Neurorescue Drugs

  2009cites this paper
• Y CONTROVERSIAS BIOSYNTHESIS OF MORPHINE : IT ́ S IMPORTANCE IN PARKINSON DISEASE

  2008cites this paper
• BIOSYNTHESIS OF MORPHINE: ITS IMPORTANCE IN PARKINSON´S DISEASE

  2008cites this paper
• Molecular characterisation of SGCE-associated myoclonus-dystonia and PINK1-associated Parkinson's disease

  2008cites this paper
• Involvement of Endoplasmic Reticulum Stress on the Cell Death Induced by 6-Hydroxydopamine in Human Neuroblastoma SH-SY5Y Cells

  2006cites this paper
• Monoamine Oxidase and Sensory Gating: Psychophysiological Vulnerabilities among Teenage Smokers

  2006cites this paper
• OPINIONES, DEBA TES Y CONTROVERSIAS

  2006cites this paper
• Differential effects of neuromelanin and synthetic dopamine melanin on cell lines Inaugural –

  2005cites this paper
• Characterization of the in vitro transcriptional activity of polymorphic alleles of the human monoamine oxidase-B gene.

  2005cites this paper
• Excessive iron accumulation in the brain: A possible potential risk of neurodegeneration in Parkinson's disease

  2005cites this paper
• Sympathetic denervation and chronic serotonin uptake blockade by fluoxetine do not affect pineal gland 5-hydroxyindole acetic acid: evidence that oxidative deamination of pineal serotonin is a property of the pinealocyte

  2005cites this paper
• Genotype combinations for monoamine oxidase-B intron 13 polymorphism and dopamine D2 receptor TaqIB polymorphism are associated with ever-smoking status among men.

  2005cites this paper
• Characterization of the role of glutathione in repin-induced mitochondrial dysfunction, oxidative stress and dopaminergic neurotoxicity in rat pheochromocytoma (PC12) cells.

  2004cites this paper
• DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson's disease cases and unrelated controls

  2004cites this paper
• Smoking and Parkinson's disease: Systematic review of prospective studies

  2004cites this paper
• Environmental Risk Factors for Parkinson's Disease

  2003cites this paper
• [Parkinson s disease risk factors].

  2003cites this paper
• Monoamine oxidase B polymorphism, cigarette smoking and risk of Parkinson's disease: A study in an Asian population

  2003cites this paper
• Case‐Control study of dopamine transporter‐1, monoamine oxidase‐B, and catechol‐O‐methyl transferase polymorphisms in Parkinson's disease

  2002cites this paper
• Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake.

  2002cites this paper
• MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD

  2002cites this paper
• Mitochondrial oxidative stress and metabolic alterations in neurodegenerative disorders

  2001cites this paper
• Estudios de asociación genética y detección de mutaciones en pacientes con enfermedad de Parkinson. Comparación genético-clínica entre los casos esporádicos y familiares.

  2001cites this paper
• The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese

  2001cites this paper
• Epidemiological studies: risk factors session IV summary and research needs.

  2001cites this paper
• - 1-SHAKING PALSY : THE ROLE OF FREE RADICALS IN THE PATHOPHYSIOLOGY OF PARKINSON ’ S DISEASE

  2001influential citation
• Epidemiological studies: risk factors session IV summary and research needs.

  2001cites this paper
• This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine

  2001influential citation
• The EcoRV genetic polymorphism of human monoamine oxidase type A is not associated with Parkinson's disease and does not modify the effect of smoking on Parkinson's disease.

  2000cites this paper
• Metallothionein in oxidative stress of Parkinson’s disease

  1999cites this paper
• Parkinson's disease--a multifactorial neurodegenerative disorder.

  1999cites this paper
• Chapter 9 The Role of Mitochondrial Genome Mutations in Neurodegenerative Disease

  1999cites this paper
• Association of a polymorphism in intron 13 of the monoamine oxidase B gene with Parkinson disease.

  1998cites this paper
• An in vitro model for analysis of oxidative death in primary mouse astrocytes.

  1998cites this paper
• Genetic aspects of Parkinson's disease

  1998cites this paper
• Platelet Monoamine Oxidase B Activity in “de novo” and L-Dopa Treated Parkinsonian Patients and Controls

  1998cites this paper
• Ligands for the dopamine D2-like receptors

  1998cites this paper
• Pharmacological aspects of human and canine narcolepsy.

  1997cites this paper
• Oxidative stress and antioxidant therapy in Parkinson's disease.

  1996cites this paper
• 0301-0082(95)00029-1 OXIDATIVE STRESS AND ANTIOXIDANT THERAPY IN PARKINSON'S DISEASE

  1996cites this paper
• Mutational analysis of the human MAOA gene.

  1996cites this paper
• Gesundheitsstörungen beim Menschen durch biogene Amine

  1996cites this paper
• Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonism

  1996cites this paper
• The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.

  1996cites this paper
• In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism

  1995cites this paper
• Oxidative stress: free radical production in neural degeneration.

  1994cites this paper
• Oxidative stress: Free radical production in neural degeneration

  1994cites this paper
• The functional role of monoamine oxidases A and B in the mammalian central nervous system.

  1994cites this paper
• Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease

  1994cites this paper
• Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.

  1994cites this paper
• Pharmacology of Monoamine Oxidase Type B Inhibitors

  1993cites this paper
• Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon.

  1993cites this paper
• Influence of monoamine oxidase inhibitors on striatonigral dynorphin system: a study with deprenyl and clorgyline.

  1993cites this paper
• The new generation of monoamine oxidase inhibitors.

  1992cites this paper
• Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease

  1992cites this paper
• Brain monoamine oxidase and aging: a review.

  1992cites this paper
• CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.

  1992cites this paper
• Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques

  1992cites this paper
• The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease

  1992cites this paper
• Monoamine oxidase, dopamine and Parkinson's disease

  1991cites this paper
• New Therapeutic Strategies in Parkinson’s Disease: Inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592

  1991cites this paper
• Rate and Cost of Hospitalizations for Asthma in Quebec : An Analysis of 1988 / 89 , 1989 / 90 and 1994 / 95 Data

  year unknowncites this paper